Alzamend Neuro Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.45 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.73Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $8.3M Enterprise Value $757.1K Shares Outstanding 4.8M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Alzamend Neuro is a high-risk, high-reward clinical-stage biopharmaceutical company developing novel therapies for major central nervous system (CNS) disorders. Its lead candidate, AL001, is a patented ionic cocrystal formulation designed to deliver therapeutic lithium to the brain with significantly lower systemic exposure than standard lithium carbonate, potentially eliminating the need for therapeutic drug monitoring. Positive Phase II topline data in healthy subjects (March 2026) demonstrated bioequivalence and numerically superior brain delivery. However, the company faces severe liquidity constraints, an accumulated deficit of over $64 million, and Nasdaq delisting risks due to stockholders' equity falling below the $2.5 million minimum. Speculative investors may find value in its low market capitalization relative to its multi-billion dollar target markets, contingent on successful capital raises and upcoming Phase II data in bipolar disorder. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$25.00 Mean target$25.00 High · most bullish analyst$25.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company fails to raise sufficient capital, leading to the suspension of clinical trials. Nasdaq delists the stock to the over-the-counter (OTC) market due to failure to meet the stockholders' equity requirement, severely reducing liquidity and causing the stock price to collapse. Base CaseCentral scenario The company successfully raises capital to fund its ongoing Phase II trial of AL001 in bipolar disorder, reporting positive topline data in Q3 2026. It submits a viable compliance plan to Nasdaq, avoiding delisting through equity issuance or a reverse stock split. Clinical progression of AL001 validates its safety profile, paving the way for partnerships. Bull CaseUpside scenario AL001 has demonstrated bioequivalence to standard lithium carbonate while delivering numerically superior lithium concentrations to the brain across all 26 measured brain regions. This targeted delivery allows for lower systemic doses, potentially eliminating the need for burdensome therapeutic drug monitoring (TDM) and mitigating the renal, thyroid, and systemic toxicity risks historically associated with lithium treatments. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |